Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

NMS Labs launches test to evaluate the efficacy of Milnacipran

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy, the potential for physicians to establish therapeutic drug monitoring of individual patients, and the assessment of drug diversion of a new pain management drug therapy.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

Virginia-based medical practice implements CTT's pain therapy medical device

Competitive Technologies, Inc. announced that a premier physician oncology practice based in Virginia has begun using CTT's Calmare® Therapy pain therapy medical device to treat patients suffering from pain related to cancer, under the direction of several medical oncologists.

24 Mar 2010

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.

17 Mar 2010

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

Injured nerves may cause severe pain in patients with sickle cell disease

Researchers at the University of Illinois at Chicago have discovered the pain caused by sickle cell disease may not occur solely from damaged tissues, but also from injured nerves.

11 Mar 2010

Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial

Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump unwanted or toxic substances away from vulnerable tissues, has announced positive results of a Phase 1a trial for its lead compound, LIM-0705, which has completed its first in man study.

10 Mar 2010

YM Biosciences announces increase of registered direct offering to $17.5M

YM BioSciences Inc., today announced that the previously announced offering of approximately US$15 million has been increased to approximately US$17.5 million.

9 Mar 2010

YM Biosciences to raise $15M in registered direct offering of common stock

YM BioSciences Inc., today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit.

5 Mar 2010

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences Inc., announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party.

3 Mar 2010

Cancer pain patients: European regulations restricting access to opioid-based drugs

Many cancer patients in Europe are being denied access to adequate pain relief because of over-zealous regulations restricting the availability and accessibility of opioid-based drugs such as morphine.

22 Feb 2010

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.

18 Feb 2010

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Alkermes, Inc. today announced positive topline data from a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).

16 Feb 2010

Third party reexamination of Phase III study of Ereska meets primary endpoint

Javelin Pharmaceuticals, Inc. today announced that a reexamination conducted by a third party of pain score measurements from its Phase III study of Ereska™ (intranasal ketamine) showed that top line results for its primary endpoint were statistically significant. Previously, Javelin had reported that the top line results for its primary endpoint were not statistically significant.

12 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

Opioids News and Research

Further Reading

NMS Labs launches test to evaluate the efficacy of Milnacipran

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Virginia-based medical practice implements CTT's pain therapy medical device

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

Injured nerves may cause severe pain in patients with sickle cell disease

Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial

YM Biosciences announces increase of registered direct offering to $17.5M

YM Biosciences to raise $15M in registered direct offering of common stock

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

Cancer pain patients: European regulations restricting access to opioid-based drugs

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Third party reexamination of Phase III study of Ereska meets primary endpoint

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News